Cameco: Why It Makes Sense To Buy The Stock At 90x Earnings

Cameco is highlighted as a vertically integrated nuclear energy operator with tier-one assets, strong long-term contract coverage, and revenue visibility that helps justify its ~90x forward earnings multiple. The article points to CCJ's 49% stake in Westinghouse and participation in the $80B U.S. reactor build-out as major upside drivers. Overall tone is bullish on secular nuclear demand and multiple compression potential.

Analysis

The market is treating CCJ less like a commodity producer and more like an infrastructure toll-road on the nuclear cycle. That matters because the incremental winner is not just uranium miners; it is the entire multi-year capital stack around fuel processing, reactor services, and project financing, while lower-quality pure plays with shorter reserve lives will struggle to justify premiums if contracting discipline remains tight. The second-order effect is that utilities facing capacity scarcity may prefer long-duration supply security over spot price exposure, which should keep term pricing firmer even if uranium equities become choppy.

The key driver of upside is duration mismatch: cash flows tied to multi-year contracts and build-out optionality can compound while the equity still marks up on near-term earnings optics. That creates a path for multiple support even from a high starting point, but it also means the stock is vulnerable to any evidence that reactor timelines slip, because the market is likely capitalizing distant growth rather than current earnings. In other words, this is less a quarterly numbers trade than a policy/permits/execution trade with a 12-36 month horizon.

Consensus may be underestimating how sensitive the thesis is to financing conditions for the reactor build-out. If rates stay elevated or public funding gets delayed, the pace of new orders could slow enough to compress sentiment before revenue is impacted, especially for suppliers with long lead times. Conversely, any US/EU policy that shortens permitting or de-risks offtake would likely force another leg higher in the whole nuclear complex, not just CCJ.

The most interesting contrarian angle is that CCJ’s premium valuation likely becomes a feature, not a bug, if the market shifts from debating earnings multiples to debating replacement cost and strategic scarcity. But if uranium prices soften while the equity remains expensive, the stock could de-rate quickly because expectations are already front-loaded. The risk/reward is therefore asymmetric: upside is path-dependent on continued execution and policy support, while downside can come from a single macro or regulatory delay.

Key Decisions for Investors

• Maintain a core long CCJ position, but size it as a policy-duration trade rather than a commodity beta trade; hold 6-18 months, and add on pullbacks only if long-term contract visibility remains intact.
• Pair trade: long CCJ / short a higher-beta uranium producer or developer with weaker balance sheet and less contracted revenue; this isolates quality and reduces exposure to a near-term uranium spot correction.
• Buy medium-dated CCJ call spreads instead of outright equity if positioning is already crowded; target a 3-6 month window around reactor-policy headlines and contract renewals, with defined downside if build-out timelines slip.
• Use a stop on CCJ if the market starts discounting reactor financing or permitting delays; a break in policy momentum would likely trigger multiple compression before fundamentals show up in reported earnings.
• Monitor utilities and nuclear supply-chain names for confirmation trade opportunities; if CCJ strength is accompanied by order acceleration, rotate into the broader nuclear basket to capture second-order upside.